Abstract
A 10-year-old boy with leukaemia-associated hypercalcaemia was treated with aminohydroxypropylidene biphosphonate (AHPrBP previously APD) in a total dosage of 60 mg over 5 days, when the condition failed to respond to rehydration and frusemide and no sustained effect was produced by haemodialysis with a calcium (Ca)-free dialysate. Bone films showed no lytic lesions, and AHPrBP, which is a potent inhibitor of osteoclast-mediated bone resorption was well tolerated and induced a rapid and sustained fall in plasma Ca (from 3.42 to 2.07 mM in 5 days). Plasma magnesium and alkaline phosphatase remained normal. The results could have been affected by other drugs [vincristine, cyclophosphamide, zorubicin (Rubidazone)l-asparaginase and prednisone] which were simultaneously administered. However, the observation that: (1) the response curve of plasma Ca was similar to that reported when AHPrBP was used alone, (2) there was complete inhibition of urinary Ca excretion and (3) hypocalcaemia occurred suggests that AHPrBP was the major cause of the reduction in plasma Ca. AHPrBP should be considered a potential therapy for hypercalcaemia in childhood malignancy.
References
Leblanc A, Hartmann O, Pons G, Caillaud JM, Couanet D, Lenoir G, Lemerle J (1984) L'hypercalcémie associée aux tumeurs de l'enfant. Arch Fr Pédiatr 41: 551–555
Stewart AF (1983) Therapy of malignancy-associated hypercalcemia. Am J Med 74: 475–480
Parfitt AM (1974) Correction of plasma calcium measurements. Br Med J 1: 520–523
Canfield RE (1987) Rationale for diphosphonate therapy in hypercalcemia of malignancy. Am J Med 82 [Suppl 2A]: 1–5
Cantwell BM, Harris AL (1987) Effect of single high dose infusions of aminohydroxypropylidène biphosphonate on hypercalcaemia caused by cancer. Br Med J 294: 467–469
Harinck AI, Bijvoet OL, Palntingh AS, Body JJ, Elte CW, Sleeboom HP, Wildiers J, Neijt JP (1987) Role of bone and kidney in tumor-induced hypercalcemia and its treatment with biphosphonate and sodium chloride. Am J Med 82: 1133–1142
Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT (1985) Comparison of aminohydroxypropylidène biphosphonate, mithramycin and corticosteroids, calcitonin in treatment of cancer-associated hypercalcemia. Lancet II: 907–910
Thiebaud D, Portmann L, Jaeger PH, Jacquet AF, Burckhardt P (1986) Oral versus intravenous AHPr1BP (APD) in the treatment of hypercalcemia of malignancy. Bone 7: 247–253
Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P (1988) Dose response in the treatment of hypercalcemia of malignancy by a single infusion of the biphosphonate AHPrBP. J Clin Oncol 6: 762–768
Van Breukelen FJ, Bijvoet OL, Frijlink WB, Sleeboom HP, Mulder H, Van Oosterom AL (1982) Efficacy of aminohydroxypropylidène biphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif Tissue Int 34: 321–327
Warrell RP (1988) Question about clinical trials in hypercalcemia. J Clin Oncol 6: 759–761
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boudailliez, B.R., Pautard, B.J., Sebert, JL. et al. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol 4, 510–511 (1990). https://doi.org/10.1007/BF00869834
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00869834